DNA (Ginkgo Bioworks Holdings, Inc.) Stock Financials & Earnings | Market Cap Arena

DNA (Ginkgo Bioworks Holdings, Inc.) Stock Financials & Earnings | Market Cap Arena

DNAGinkgo Bioworks Holdings, Inc.

Mkt Cap$418M

Healthcare·Biotechnology·🇺🇸 United States·NYSE

Revenue (TTM)$170M

Net Income (TTM)-$313M

EPS (TTM)-$5.66

Free Cash Flow (TTM)-$194M

Gross Margin81.5%

Op. Margin-185.3%

Net Margin-183.8%

FCF Margin-114.0%

P/S Ratio (TTM)2.5x

P/E Ratio (TTM)—

YoY Rev Growth-25.1%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$81M	$58M	-$216M
Q2 23	$81M	$62M	-$184M
Q3 23	$55M	$49M	-$286M
Q4 23	$35M	$28M	-$178M
Q1 24	$38M	$29M	-$178M
Q2 24	$56M	$42M	-$223M
Q3 24	$89M	$79M	-$55M
Q4 24	$44M	$34M	-$104M
Q1 25	$48M	$36M	-$89M
Q2 25	$50M	$35M	-$66M
Q3 25	$39M	$26M	-$90M
Q4 25	$33M	$42M	-$71M

Valuation

Quarter	P/S	P/E
Q1 23	1.1x	—
Q2 23	1.3x	—
Q3 23	1.3x	—
Q4 23	1.7x	—
Q1 24	2.0x	—
Q2 24	2.3x	—
Q3 24	1.9x	—
Q4 24	1.8x	—
Q1 25	1.8x	—
Q2 25	1.8x	—
Q3 25	2.3x	—
Q4 25	2.5x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$91M	-$110M
Q2 23	-$74M	-$87M
Q3 23	-$74M	-$78M
Q4 23	-$58M	-$61M
Q1 24	-$89M	-$96M
Q2 24	-$84M	-$111M
Q3 24	-$104M	-$119M
Q4 24	-$42M	-$56M
Q1 25	-$52M	-$59M
Q2 25	-$40M	-$40M
Q3 25	-$32M	-$32M
Q4 25	-$48M	-$63M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$19M
Q2 23	$14M
Q3 23	$4M
Q4 23	$3M
Q1 24	$7M
Q2 24	$27M
Q3 24	$15M
Q4 24	$14M
Q1 25	$8M
Q2 25	$38K
Q3 25	$0
Q4 25	$15M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	-52.1%	-64.9%
Q2 23	-44.3%	-66.6%
Q3 23	-16.5%	-52.6%
Q4 23	-64.6%	-36.0%
Q1 24	-53.0%	-27.2%
Q2 24	-30.2%	+5.5%
Q3 24	+60.6%	-57.8%
Q4 24	+26.2%	-30.7%
Q1 25	+27.3%	-36.4%
Q2 25	-11.7%	-58.8%
Q3 25	-56.4%	-10.7%
Q4 25	-23.8%	-29.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$0	0.0%
Q2 23	$0	0.0%
Q3 23	$53M	94.8%
Q4 23	$0	0.0%
Q1 24	$41M	107.5%
Q2 24	$37M	66.1%
Q3 24	$0	0.0%
Q4 24	$21M	46.9%
Q1 25	$20M	42.3%
Q2 25	$22M	44.8%
Q3 25	$18M	45.9%
Q4 25	$21M	63.0%

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$163M	$111M
Q2 23	$144M	$102M
Q3 23	$157M	$82M
Q4 23	$117M	$89M
Q1 24	$136M	$70M
Q2 24	$134M	$66M
Q3 24	$77M	$52M
Q4 24	$76M	$57M
Q1 25	$71M	$49M
Q2 25	$53M	$43M
Q3 25	$69M	$45M
Q4 25	$50M	$46M

Revenue Segments

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$1.2B	$0	$1.2B
Q2 23	$1.1B	$0	$1.1B
Q3 23	$1.0B	$0	$1.0B
Q4 23	$944M	$0	$944M
Q1 24	$844M	$0	$844M
Q2 24	$730M	$0	$730M
Q3 24	$616M	$0	$616M
Q4 24	$562M	$0	$562M
Q1 25	$312M	$205M	$517M
Q2 25	$204M	$270M	$474M
Q3 25	$111M	$351M	$462M
Q4 25	$167M	$255M	$423M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	48M	+3.2%
Q2 23	48M	+0.9%
Q3 23	49M	+0.9%
Q4 23	49M	+1.4%
Q1 24	50M	+1.1%
Q2 24	51M	+2.8%
Q3 24	52M	+1.7%
Q4 24	52M	-0.7%
Q1 25	54M	+4.5%
Q2 25	55M	+1.1%
Q3 25	56M	+1.4%
Q4 25	55M	-0.3%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 19	—	—
FY 20	—	—
FY 21	$490K	641
FY 22	$370K	1K
FY 23	$206K	1K
FY 24	$272K	834
FY 25	$351K	485